ArticleOTO open
Trends in Medicare Office-Based Procedures for Chronic Rhinitis and Nasal Obstruction.
Article in OTO open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine national trends in Medicare office-based procedures for chronic rhinitis and nasal obstruction, emphasizing minimally invasive interventions such as posterior nasal nerve (PNN) ablation and nasal valve repair with radiofrequency ablation. Study Design: Retrospective longitudinal analysis of Medicare physician and provider utilization data from 2017 to 2023. Setting: Office-based procedural care across the United States. Methods: Current Procedural Terminology (CPT) codes 30117 (destruction of intranasal lesion), 30140 (inferior turbinate submucous resection), 31295 (maxillary balloon dilation), and 30802 (radiofrequency inferior turbinate reduction) were analyzed, focusing on office-based procedures. CPT 30117 served as a surrogate for PNN ablation and nasal valve repair using radiofrequency ablation. Annual service counts, beneficiaries, Medicare payments, total spending, provider-level adoption, geographic distribution, and early adopter patterns were analyzed. Linear regression evaluated trends over time ( Results: From 2017 to 2023, CPT 30117 services rose from 1009 to 11,409 (compound annual growth rate [CAGR] 49.8%), 30140 increased from 3218 to 5792 (CAGR 10.3%), 31295 slightly declined (10,3120 → 9180; CAGR -1.9%), and 30802 declined from 1353 to 863 (CAGR -7.2%). Spending grew sharply for 30117 ($0.41M → $5.08M; +1139%) and 31295 ($12.36M → $15.4M; +25%), modestly for 30140 ($0.89M → $1.05M; +18%), and declined for 30802 ($0.19M → $0.10M; -47%). Texas, Florida, and Arizona had concentrated utilization. Conclusion: In-office use of CPT 30117 has grown rapidly, outpacing other nasal procedures, reflecting the adoption of new PNN ablation and nasal airway remodeling devices. These trends underscore the need for ongoing evidence development, with further clarification anticipated following new device and procedure-specific coding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.